Literature DB >> 30256773

Refining the management of polycythemia vera.

Ruben A Mesa1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30256773      PMCID： PMC8148984     

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  6 in total

1.  Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.

Authors:  Srdan Verstovsek; Alessandro M Vannucchi; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Keita Kirito; Carlos Besses; Masayuki Hino; Beatriz Moiraghi; Carole B Miller; Mario Cazzola; Vittorio Rosti; Igor Blau; Ruben Mesa; Mark M Jones; Huiling Zhen; Jingjin Li; Nathalie Francillard; Dany Habr; Jean-Jacques Kiladjian
Journal:  Haematologica       Date:  2016-04-21       Impact factor: 9.941

2.  Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.

Authors:  Giovanni Barosi; Ruben Mesa; Guido Finazzi; Claire Harrison; Jean-Jacques Kiladjian; Eva Lengfelder; Mary F McMullin; Francesco Passamonti; Alessandro M Vannucchi; Carlos Besses; Heinz Gisslinger; Jan Samuelsson; Srdan Verstovsek; Ronald Hoffman; Animesh Pardanani; Francisco Cervantes; Ayalew Tefferi; Tiziano Barbui
Journal:  Blood       Date:  2013-04-16       Impact factor: 22.113

3.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

4.  Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.

Authors:  Francesco Passamonti; Martin Griesshammer; Francesca Palandri; Miklos Egyed; Giulia Benevolo; Timothy Devos; Jeannie Callum; Alessandro M Vannucchi; Serdar Sivgin; Caroline Bensasson; Mahmudul Khan; Nadjat Mounedji; Guray Saydam
Journal:  Lancet Oncol       Date:  2016-12-02       Impact factor: 41.316

5.  Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.

Authors:  Heinz Gisslinger; Oleh Zagrijtschuk; Veronika Buxhofer-Ausch; Josef Thaler; Ernst Schloegl; Guenther A Gastl; Dominik Wolf; Robert Kralovics; Bettina Gisslinger; Karin Strecker; Alexander Egle; Thomas Melchardt; Sonja Burgstaller; Ella Willenbacher; Martin Schalling; Nicole C Them; Pavla Kadlecova; Christoph Klade; Richard Greil
Journal:  Blood       Date:  2015-08-10       Impact factor: 22.113

6.  Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.

Authors:  Lucia Masarova; Keyur P Patel; Kate J Newberry; Jorge Cortes; Gautam Borthakur; Marina Konopleva; Zeev Estrov; Hagop Kantarjian; Srdan Verstovsek
Journal:  Lancet Haematol       Date:  2017-03-11       Impact factor: 18.959
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.